drugset / Trial / NCT04238988
Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Phase 2
Unknown
45 enrolled
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
Single arm multicenter phase II trial evaluating the role of Pembrolizumab in combination to Carboplatin-Paclitaxel chemotherapy in locally advanced cervical cancer patients.
Timeline
- Start
- 2021-02-18
- Primary completion
- 2023-09-01
- Completion
- 2023-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |